Privium Fund Management B.V. holds a focused book of 61 stocks worth $544.2M as of Q2 2026 (disclosed Aug 7, 2026, a ~38-day 13F lag). This quarter they opened Opendoor Technologies Inc and trimmed Shopify Inc - Class A. Their largest long position is Tesla Inc at 18% of the equity book.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Privium Fund Management B.V.
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| JPMORGAN CHASE & CO | 68 / 61 | $148.4B |
| MORGAN STANLEY | 68 / 61 | $143.0B |
| UBS Group AG | 68 / 61 | $34.0B |
| WELLS FARGO & COMPANY/MN | 68 / 61 | $24.0B |
| ROYAL BANK OF CANADA | 67 / 61 | $36.8B |
| BNP PARIBAS FINANCIAL MARKETS | 67 / 61 | $15.3B |
| BlackRock, Inc. | 66 / 61 | $698.9B |
| BARCLAYS PLC | 66 / 61 | $31.6B |
Ranked by how many of Privium Fund Management B.V.'s top 61 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Tesla Inc COM | $95.9M | 228.0K | 17.6% | ▲+2.7% Added · +6K sh | |
| 2 | Shopify Inc CL A SUB VTG SHS | $42.2M | 370.0K | 7.8% | ▼−9.1% Reduced · −37K sh | |
| 3 | Advanced Micro Devices Inc COM | $36.0M | 62.0K | 6.6% | —Held | |
| 4 | Amazon Com Inc COM | $33.4M | 140.0K | 6.1% | ▲+12% Added · +15K sh | |
| 5 | Ionis Pharmaceuticals Inc COM | $25.4M | 319.9K | 4.7% | ▲+10% Added · +30K sh | |
| 6 | Spotify Technology S A SHS | $25.3M | 55.0K | 4.6% | ▼−18% Reduced · −12K sh | |
| 7 | Palantir Technologies Inc CL A | $23.3M | 200.0K | 4.3% | —Held | |
| 8 | Arrowhead Pharmaceuticals In COM | $19.1M | 234.2K | 3.5% | ▼−36% Reduced · −133K sh | |
| 9 | Opendoor Technologies Inc COM | $18.2M | 3.94M | 3.3% | ▲New New position | |
| 10 | Lemonade Inc COM | $17.6M | 270.3K | 3.2% | ▲+5.9% Added · +15K sh | |
| 11 | Nvidia Corporation COM | $16.2M | 81.0K | 3.0% | —Held | |
| 12 | Iren Limited ORDINARY SHARES | $15.6M | 340.1K | 2.9% | ▲+6.2% Added · +20K sh | |
| 13 | Uniqure NV SHS | $15.1M | 328.3K | 2.8% | ▼−33% Reduced · −158K sh | |
| 14 | Cerebras Systems Inc COM CL A *A* | $13.4M | 60.5K | 2.5% | ▲New New position | |
| 15 | Ast Spacemobile Inc COM CL A | $12.9M | 145.0K | 2.4% | —Held | |
| 16 | Ultragenyx Pharmaceutical In COM | $11.3M | 338.8K | 2.1% | ▼−7.1% Reduced · −26K sh | |
| 17 | Arcutis Biotherapeutics Inc COM | $10.5M | 399.4K | 1.9% | ▲+24% Added · +78K sh | |
| 18 | Biogen Inc COM | $10.5M | 48.4K | 1.9% | ▲+11% Added · +5K sh | |
| 19 | Proqr Thrapeutics N V SHS EURO | $10.3M | 5.52M | 1.9% | ▲+1.0% Added · +53K sh | |
| 20 | Axsome Therapeutics Inc. COM | $9.8M | 39.9K | 1.8% | ▼−32% Reduced · −19K sh | |
| 21 | Urogen Pharma Ltd COM | $7.7M | 210.0K | 1.4% | ▼−12% Reduced · −28K sh | |
| 22 | Space Exploration Techn Corp CLASS A COM STK *A* | $6.8M | 40.0K | 1.3% | ▲New New position | |
| 23 | Denali Therapeutics Inc COM | $5.9M | 229.9K | 1.1% | ▼−9.8% Reduced · −25K sh | |
| 24 | Vertex Pharmaceuticals Inc COM | $4.7M | 9.4K | 0.9% | ▼−17% Reduced · −2K sh | |
| 25 | Biomarin Pharmaceutical Inc COM | $4.3M | 75.0K | 0.8% | ▼−19% Reduced · −17K sh | |
| 26 | Krystal Biotech Inc COM | $4.2M | 11.2K | 0.8% | —Held | |
| 27 | Alnylam Pharmaceuticals Inc COM | $3.4M | 11.4K | 0.6% | ▼−7.0% Reduced · −850 sh | |
| 28 | Viridian Therapeutics Inc COM | $3.2M | 173.5K | 0.6% | —Held | |
| 29 | Biontech SE SPONSORED ADS | $2.8M | 30.1K | 0.5% | ▲+11% Added · +3K sh | |
| 30 | Hims & Hers Health Inc COM CL A | $2.8M | 80.0K | 0.5% | ▲+100% Added · +40K sh | |
| 31 | Meiragtx Hldgs PLC COM | $2.6M | 196.1K | 0.5% | ▼−7.5% Reduced · −16K sh | |
| 32 | Ambev Sa SPONSORED ADR | $2.5M | 802.2K | 0.5% | ▼−15% Reduced · −146K sh | |
| 33 | Sarepta Therapeutics Inc COM | $2.5M | 136.5K | 0.5% | ▲+197% Added · +91K sh | |
| 34 | Crispr Therapeutics AG NAMEN AKT | $2.5M | 45.0K | 0.5% | ▲+4.9% Added · +2K sh | |
| 35 | Beam Therapeutics Inc COM | $2.4M | 70.3K | 0.4% | ▲+9.8% Added · +6K sh | |
| 36 | Zai Lab Ltd ADR | $2.3M | 122.2K | 0.4% | ▼−7.6% Reduced · −10K sh | |
| 37 | Moderna Inc COM | $2.1M | 30.0K | 0.4% | —Held | |
| 38 | Cartesian Therapeutics Inc COM NEW | $1.6M | 151.7K | 0.3% | ▼−15% Reduced · −27K sh | |
| 39 | Magnum Ice Cream Co NV ORD SHS | $1.5M | 98.2K | 0.3% | ▲New New position | |
| 40 | Wave Life Sciences Ltd SHS | $1.4M | 241.0K | 0.3% | —Held | |
| 41 | Taysha Gene Therapies Inc COM SHS | $1.4M | 198.9K | 0.2% | ▲+9.3% Added · +17K sh | |
| 42 | Zoetis Inc CL A | $1.2M | 17.3K | 0.2% | ▲New New position | |
| 43 | 4D Molecular Therapeutics In COM | $1.2M | 90.1K | 0.2% | ▼−47% Reduced · −80K sh | |
| 44 | Fate Therapeutics Inc COM | $1.1M | 414.3K | 0.2% | —Held | |
| 45 | Legend Biotech Corp SPONSORED ADS | $1.0M | 35.4K | 0.2% | ▲New New position | |
| 46 | Rocket Pharmaceuticals Inc COM | $835K | 244.1K | 0.2% | ▲+0.8% Added · +2K sh | |
| 47 | Nov Inc COM | $780K | 42.0K | 0.1% | —Held | |
| 48 | B2gold Corp COM | $730K | 195.1K | 0.1% | ▲+102% Added · +99K sh | |
| 49 | Totalenergies SE ACT | $729K | 10.7K | 0.1% | ▲New New position | |
| 50 | Lexeo Therapeutics Inc COM | $722K | 155.0K | 0.1% | ▼−24% Reduced · −50K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1795097/holdings"
Use Arkolith to show Privium Fund Management B.V.'s latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.